News
BDTX ▲ +10.9% - Black Diamond Therapeutics, Inc.
BDTX ▲ +10.9% - Black Diamond Therapeutics, Inc.
$BDTX - Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC
09-NOV-2026 04:01 PM ET
Share this post
More filings for $BDTX
BDTX ▲ +4.4% - Black Diamond Therapeutics, Inc.Sep 2, 2026$BDTX SEC Filing Update (27-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 27, 2026$BDTX SEC Filing Update (08-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 8, 2026
View full $BDTX filing history →💬 Comments
Loading comments…
Leave a comment